|Bid||22.00 x 900|
|Ask||32.00 x 2200|
|Day's Range||25.60 - 26.29|
|52 Week Range||16.68 - 29.80|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||39.11|
|Earnings Date||Feb 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
WINTER SPRINGS, Fla., Jan. 22, 2020 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 fourth quarter financial results before.
Today we'll look at IRadimed Corporation (NASDAQ:IRMD) and reflect on its potential as an investment. Specifically...
IRADIMED CORPORATION (IRMD) announced the retirement of Brent Johnson, Executive Vice President of Worldwide Sales and Marketing, effective April 10, 2020 after leading the Company’s commercial efforts since 2012. IRADIMED appointed MaryBeth Smith as Vice President of Worldwide Sales, succeeding Mr. Johnson, effective January 20, 2020. Ms. Smith will report to Leslie McDonnell, President and Chief Executive Officer.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
IRADIMED CORPORATION (IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring system that are designed for use during MRI procedures, today announced that it resumed shipments of its MRI compatible patient vital signs monitoring systems into European Commission markets after completing the CE Mark renewal process.
Anyone interested in IRadimed Corporation (NASDAQ:IRMD) should probably be aware that the Independent Director, Monty...
iRadimed (IRMD) delivered earnings and revenue surprises of 53.33% and 1.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23Updates full-year financial guidance WINTER SPRINGS, Fla., Oct..
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WINTER SPRINGS, Fla., Oct. 16, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 third quarter financial results before the.
IRADIMED CORPORATION (IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. “The resolution of the warning letter is the result of countless hours of work performed by everyone at IRADIMED. The Company does not expect a significant impact to its business or financial performance resulting from the close-out letter.
IRadimed Corporation (NASDAQ:IRMD) shareholders have seen the share price descend 13% over the month. But that doesn't...
To Cut Or Not to Cut? Lagarde Answers the Question Federal Reserve officials are prevaricating over whether to cut dollar interest rates at the next Federal Open Market Committee meeting on September 17-18. St. Louis Fed President James Bullard is the most dovish (from the inflation side) and hawkish (from the saver side) calling for […]The post Market Morning: Fed Debates, Johnson Loses, Hong Kong Wins, Italy Gets New Government appeared first on Market Exclusive.
WINTER SPRINGS, Fla., Aug. 27, 2019 -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman.
If you own shares in IRadimed Corporation (NASDAQ:IRMD) then it's worth thinking about how it contributes to the...
In these days of wild market fluctuations, revisiting your portfolio through the dual lenses of circles of competence and comfort can be quite helpful Continue reading...
iRadimed (IRMD) delivered earnings and revenue surprises of 33.33% and 3.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Reports second quarter 2019 revenue of $9.2 millionReports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20Updates full year earnings guidance.